These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 24052461)

  • 21. Key predictive factors of axitinib (AG-013736)-induced proteinuria and efficacy: a phase II study in Japanese patients with cytokine-refractory metastatic renal cell Carcinoma.
    Tomita Y; Uemura H; Fujimoto H; Kanayama HO; Shinohara N; Nakazawa H; Imai K; Umeyama Y; Ozono S; Naito S; Akaza H;
    Eur J Cancer; 2011 Nov; 47(17):2592-602. PubMed ID: 21889330
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Vascular endothelial growth factor inhibitor-induced hypertension: from pathophysiology to prevention and treatment based on long-acting nitric oxide donors.
    Kruzliak P; Novák J; Novák M
    Am J Hypertens; 2014 Jan; 27(1):3-13. PubMed ID: 24168915
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Identification and analysis of in vivo VEGF downstream markers link VEGF pathway activity with efficacy of anti-VEGF therapies.
    Brauer MJ; Zhuang G; Schmidt M; Yao J; Wu X; Kaminker JS; Jurinka SS; Kolumam G; Chung AS; Jubb A; Modrusan Z; Ozawa T; James CD; Phillips H; Haley B; Tam RN; Clermont AC; Cheng JH; Yang SX; Swain SM; Chen D; Scherer SJ; Koeppen H; Yeh RF; Yue P; Stephan JP; Hegde P; Ferrara N; Singh M; Bais C
    Clin Cancer Res; 2013 Jul; 19(13):3681-92. PubMed ID: 23685835
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Vascular endothelial growth factor inhibitors and cognitive impairment: evidence and controversies.
    Ng T; Cheung YT; Ng QS; Ho HK; Chan A
    Expert Opin Drug Saf; 2014 Jan; 13(1):83-92. PubMed ID: 23931162
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Renovascular effects of antiangiogenic drugs].
    Deray G; Janus N; Aloy B; Launay-Vacher V
    Bull Cancer; 2016; 103(7-8):662-6. PubMed ID: 27318610
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects.
    Kappers MH; van Esch JH; Sleijfer S; Danser AH; van den Meiracker AH
    J Hypertens; 2009 Dec; 27(12):2297-309. PubMed ID: 19680138
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Clinicopathological features of kidney injury in patients receiving immune checkpoint inhibitors (ICPi) combined with anti-vascular endothelial growth factor (anti-VEGF) therapy.
    Jin S; Shen Z; Li J; Liu X; Zhu Q; Li F; Shi Y; Lin P; Xu X; Chen X; Geng X; Ding X; Liu H
    J Clin Pathol; 2024 Jun; 77(7):471-477. PubMed ID: 38242556
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Response to anti-angiogenesis: an ever changing feature.
    Bertolini F
    Breast; 2011 Oct; 20 Suppl 3():S61-2. PubMed ID: 22015295
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Renal effects of anti-angiogenesis therapy: update for the internist.
    Gurevich F; Perazella MA
    Am J Med; 2009 Apr; 122(4):322-8. PubMed ID: 19332223
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phase I study of antisense oligonucleotide against vascular endothelial growth factor: decrease in plasma vascular endothelial growth factor with potential clinical efficacy.
    Levine AM; Tulpule A; Quinn DI; Gorospe G; Smith DL; Hornor L; Boswell WD; Espina BM; Groshen SG; Masood R; Gill PS
    J Clin Oncol; 2006 Apr; 24(11):1712-9. PubMed ID: 16520466
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Mechanism of hypertension and proteinuria during angiogenesis inhibition: evolving role of endothelin-1.
    Lankhorst S; Kappers MH; van Esch JH; Danser AH; van den Meiracker AH
    J Hypertens; 2013 Mar; 31(3):444-54; discussion 454. PubMed ID: 23221987
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cutaneous manifestations of anti-angiogenic therapy in oncology: Review with focus on VEGF inhibitors.
    Ishak RS; Aad SA; Kyei A; Farhat FS
    Crit Rev Oncol Hematol; 2014 May; 90(2):152-64. PubMed ID: 24355408
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Anti-vascular endothelial growth factor therapy in the era of personalized medicine.
    Féliz LR; Tsimberidou AM
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):1-12. PubMed ID: 23463481
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Nitric oxide and adverse events of vascular endothelial growth factor inhibitors.
    Thachil J
    Curr Med Res Opin; 2011 Aug; 27(8):1503-7. PubMed ID: 21651424
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The role of vascular endothelial growth factor in pulmonary arterial hypertension. The angiogenesis paradox.
    Voelkel NF; Gomez-Arroyo J
    Am J Respir Cell Mol Biol; 2014 Oct; 51(4):474-84. PubMed ID: 24932885
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Nephrotoxicity--proteinuria and hypertension--].
    Ando M
    Gan To Kagaku Ryoho; 2008 Oct; 35(10):1649-53. PubMed ID: 18931564
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Selected adverse events in cancer patients treated with vascular endothelial growth factor inhibitors.
    Dreyfus B; Kawabata H; Gomez A
    Cancer Epidemiol; 2013 Apr; 37(2):191-6. PubMed ID: 23246035
    [TBL] [Abstract][Full Text] [Related]  

  • 38. VEGF inhibition, hypertension, and renal toxicity.
    Hayman SR; Leung N; Grande JP; Garovic VD
    Curr Oncol Rep; 2012 Aug; 14(4):285-94. PubMed ID: 22544560
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review.
    Eskens FA; Verweij J
    Eur J Cancer; 2006 Dec; 42(18):3127-39. PubMed ID: 17098419
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Antiangiogenic therapies: is VEGF-A inhibition alone enough?
    Gordon MS
    Expert Rev Anticancer Ther; 2011 Mar; 11(3):485-96. PubMed ID: 21417860
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.